Close

Needham & Company Maintains a 'Buy' on Dyax Corp. (DYAX); Strong Kalbitor Growth Trends

July 20, 2012 8:24 AM EDT
Get Alerts DYAX Hot Sheet
Price: $38.41 --0%

Rating Summary:
    3 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Needham & Company maintains a 'Buy' on Dyax Corp. (NASDAQ: DYAX) price target of $3.50.

Analyst, Serge Belanger, said, "DYAX reported another quarter of impressive Kalbitor growth. Management continues to show solid commercial execution with a comprehensive set of patient support and services programs (i.e., home infusion service) driving patient enrollment and treatment rates. Kalbitor is also benefitting from updated HAE treatment guidelines that emphasize the use of on-demand treatments. DYAX stock has had an impressive performance over the last Q, benefitting from stable Kalbitor growth and investors’ increased appetite for small-cap biotech."

Raises FY12/13 EPS estimate by $0.01 to (0.35) and (0.16), respectively.


For an analyst ratings summary and ratings history on Dyax Corp. click here. For more ratings news on Dyax Corp. click here.

Shares of Dyax Corp. closed at $2.72 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Needham & Company